Diabetes Drugs Affect Hearts of Men, Women Differently

Contact Information

Available for logged-in reporters only

Newswise Widely used treatments for type 2 diabetes have different effects on the hearts of men and women, even as the drugs control blood sugar equally well in both sexes, according to researchers at Washington University School of Medicine in St. Louis.

In particular, the commonly prescribed diabetes drug metformin had positive effects on heart function in women but not in men, who experienced a shift in metabolism thought to increase the risk of heart failure.

We saw dramatic sex differences in how the heart responds to the different therapies, said senior author Robert J. Gropler, MD, professor of radiology. Our study suggests that we need to better define which therapies are optimal for women with diabetes and which ones are optimal for men.

The study appears in the December issue of the American Journal of Physiology - Heart and Circulatory Physiology.

To the researchers knowledge, this is the first study to investigate sex differences in the hearts response to diabetes treatments. In type 2 diabetes, the pancreas continues to make insulin, but the body cant use it effectively to move glucose out of the blood and into the tissues. And for reasons that are not entirely clear, patients with diabetes are at higher risk for heart failure.

It is imperative that we gain understanding of diabetes medications and their impact on the heart in order to design optimal treatment regimens for patients, said Janet B. McGill, MD, professor of medicine and a study co-author who sees patients at Barnes-Jewish Hospital. This study is a step in that direction.

The investigators evaluated commonly prescribed diabetes drugs in 78 patients, who were assigned to one of three groups. Under McGills supervision, the first group received metformin alone; the second received metformin plus rosiglitazone (Avandia); and the third received metformin plus Lovaza, which is a kind of fish oil.

Metformin reduces glucose production by the liver and helps the body become more sensitive to insulin. Rosiglitazone also improves insulin sensitivity and is known to move free fatty acids out of the blood. Lovaza is prescribed to lower blood levels of triglycerides, another type of fat.

Link:
Diabetes Drugs Affect Hearts of Men, Women Differently

For Altitude Training, a Narrow Window for Success

Contact Information

Available for logged-in reporters only

Article is published in the Journal of Applied Physiology

Newswise Bethesda, Md. (Dec. 12, 2013)Researchers and athletes have long known that living at altitude holds the potential to improve athletic performance. Many competitive endurance athletes follow a Live High Train Low training regimen, in which they live at moderate altitudes and do their easiest workouts there, saving their most intense training for altitudes closer to sea level. However, though several studies have shown the promise of this type of training philosophy, its been unknown what specific living altitude is best for enhancing athletic performance at sea level.

To help answer this question, lead researchers Benjamin D. Levine of the Institute for Exercise and Environmental Medicine at Texas Health Resources and the UT Southwestern Medical Center and James Stray-Gundersen of the USA Ski and Snowboard Association, along with first author Robert F. Chapman of Indiana University and colleagues flew competitive collegiate runners from Dallas, Texasa city near sea levelto one of four different altitude training camps at various heights in the mountains near Salt Lake City, Utah, where they lived and trained for a month. Prior to and after the altitude training camp, they tested these athletes performance in a 3000 meter time trial in Dallas. The researchers findings show that living between 2000 and 2500 meters above sea level offered the best performance enhancement compared to living at higher or lower elevations. These findings could help competitive endurance athletes and their coaches develop altitude training regimens that have the highest chance of success.

The article is entitled Defining the Dose of Altitude Training: How High to Live for Optimal Sea Level Performance Enhancement. It appears in the Articles in Press section of the Journal of Applied Physiology, published by the American Physiological Society. The article is available online at http://bit.ly/1bh6dNr.

Methodology The researchers worked with 48 collegiate track and cross country runners. For four weeks, these athletes trained in Dallas, where the researchers performed a variety of tests to assess the athletes baselines on several different measures. For example, they determined the athletes VO2max, a measure of aerobic fitness based on the rate at which the body uses oxygen during exercise. They timed the athletes as they ran 3000 meters at their fastest pace. They performed a variety of blood tests, including measuring their volume of red blood cells and the concentration of a hormone called EPO that stimulates red blood cell production. Previous research has shown that EPO concentrations rise when people live at higher altitudes, an adaptation to help their bodies cope with less oxygen in the air by making more red blood cells.

Then, for a second four weeks, these athletes were separated into four groups. Each group lived in altitude training camps in the mountains near Salt Lake City at sites of various altitudes: Heber City (1780 meters), Park City (2085 meters), Deer Valley (2454 meters), and Guardsmans Pass (2800 meters). Once a day, all the athletes gathered at a common site to train regardless of which altitude they were assigned for living. Their EPO concentrations were checked periodically during their mountain stay.

At the end of this period, the athletes regrouped in Dallas, where they had more exercise and blood testing and ran another timed 3000 meters.

Results The researchers found that when the athletes returned to sea level, only those who lived at the two middle altitudes (2085m and 2454m) performed significantly better than those at either end of the spectrum. EPO concentrations and red blood cell volumes had risen in each of the four groups, suggesting that contrary to long-held wisdom, these adaptations arent the only reason altitude training enhances performance.

Go here to see the original:
For Altitude Training, a Narrow Window for Success

Men’s and Women’s Hearts React Differently to Diabetes Drug

December 12, 2013

Brett Smith for redOrbit.com Your Universe Online

In a new study from researchers at at Washington University School of Medicine, the type 2 diabetes drug metformin was found to have different effects on the hearts of men and women, despite managing blood sugar the same in both sexes.

According to the study, which was published in the December issue of the American Journal of Physiology Heart and Circulatory Physiology, the drug had positive effects on womens heart health, but male patients saw a change in heart function associated with increased risk for heart failure.

We saw dramatic sex differences in how the heart responds to the different therapies, said study author Robert J. Gropler, a professor of radiology at WUStL. Our study suggests that we need to better define which therapies are optimal for women with diabetes and which ones are optimal for men.

The pancreas continues to make insulin in patients with type 2 diabetes, but the body isnt able to effectively use it to draw glucose out of the blood and into the tissues. Type 2 diabetes is also linked to an increased risk for heart failure.

It is imperative that we gain understanding of diabetes medications and their impact on the heart in order to design optimal treatment regimens for patients, said study author Dr. Janet B. McGill, also a professor of medicine at WUStL. This study is a step in that direction.

In the study, researchers looked at commonly prescribed diabetes drugs in 78 patients. The study participants were divided into one of three groups: those receiving metformin alone, those receiving metformin and rosiglitazone (Avandia) and those receiving metformin plus Lovaza, a form of fish oil.

While metformin reduces glucose production by the liver, rosiglitazone is known to draw free fatty acids out of the blood. Both drugs boost the bodys sensitivity to insulin. Lovaza is prescribed to reduce levels of fatty triglycerides in the blood.

The three groups did not exhibit any major differences in heart metabolism. However, when the patients were divided by sex, the drugs were seen as having different and sometimes opposite effects on heart metabolism.

Original post:
Men’s and Women’s Hearts React Differently to Diabetes Drug

Hemophilia and long-term HIV infection — is there a protective link?

PUBLIC RELEASE DATE:

11-Dec-2013

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, December 11, 2013People with the genetic blood clotting disorder hemophilia who have been infected with HIV for decades have an increased proportion of immune cells in their blood that specifically target HIV. This protective immune response helps chronically infected hemophilia patients survive, even during periods of HIV activity, according to a study published in BioResearch Open Access, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the BioResearch Open Access website.

Volker Daniel and colleagues, University of Heidelberg and Kurpfalz Hospital, Germany, compared the levels of a class of HIV-reactive immune cells called CD8+ lymphocytes in the blood of hemophilia patients infected with HIV for 30 years and in health individuals. They present the results in "HIV-Specific CD8+ T Lymphocytes in Blood of Long-Term HIV-Infected Hemophilia Patients."

"Understanding the reasons for long-term clinical stability in hemophilia patients living with HIV remains an important research goal, with high clinical significance," says BioResearch Open Access Editor Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland. "Using a unique cohort of patients, who have been living with HIV-1 for more than 30 years, the authors propose that it is the cellular anti-HIV-1 response in combination with anti-retroviral therapy that ensures the long-term survival of these patients."

###

About the Journal

BioResearch Open Access is a bimonthly peer-reviewed open access journal led by Editor-in-Chief Robert Lanza, MD, Chief Scientific Officer, Advanced Cell Technology, Inc. and Editor Jane Taylor, PhD. The Journal provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available on the BioResearch Open Access website.

About the Publisher

More here:
Hemophilia and long-term HIV infection -- is there a protective link?

[WEBINAR] Tips for Effective Mobile Marketing to Life Scientists – Hosted by GEN

Arlington, VA (PRWEB) December 10, 2013

Join us for this free 60-minute webinar on December 12, 2013 at 2:00PM EST/11:00AM PST, as Genetic Engineering & Biotechnology News hosts BioInformatics LLC and other top industry leaders from Life Technologies and Chempetitive Group to discuss effective mobile marketing practices for reaching life scientists.

According to a recent study, one-third of scientists engage in social media either weekly or daily to support their research. And some scientists are constantly using social media for non-work related activities, which indicates that they are also more likely to spend time on social media sites to support their research.

GENs upcoming webinar will tell you what you need to know to reach life scientists who say they want to learn about products and services on mobile devices. Learn specifics about mobile adoption by life scientists, content and messaging unique to the mobile channel, and examples of successful mobile marketing campaigns by a top industry player.

Moderated by: Bill Levine, Director of Digital Media for Genetic Engineering & Biotechnology News

Register for free at the link below: https://cc.readytalk.com/cc/s/registrations/new?cid=h189p3vc56tl

PRESENTER INFO

Bill Kelly, President, BioInformatics LLC Provider of critical market intelligence to major suppliers serving the life science, medical device and pharmaceutical industries.

Jon Young, Senior Manager, Mobile eBusiness, Life Technologies Provider of products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences.

Jeremiah Worth, Director of Digital Strategy, Chempetitive Group Integrated life science marketing agency providing creative, digital, branding and PR services.

Here is the original post:
[WEBINAR] Tips for Effective Mobile Marketing to Life Scientists - Hosted by GEN

New study shows a breadth of antisense drug activity across many different organs

PUBLIC RELEASE DATE:

10-Dec-2013

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, December 10, 2013Antisense therapeutics, a class of drugs comprised of short nucleic acid sequences, can target a dysfunctional gene and silence its activity. A new study has shown that antisense drugs delivered systemically show activity in a wide range of tissues and organs, supporting their broad therapeutic potential in many disease indications, as described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Nucleic Acid Therapeutics website.

Gene Hung, Xiaokun Xiao, Raechel Peralta, Gourab Bhattacharjee, Sue Murray, Dan Norris, Shuling Guo, and Brett Monia, Isis Pharmaceuticals, Carlsbad, CA, developers of antisense therapeutics, compared two antisense drug chemistries (Generation 2.0 and 2.5) designed to target a gene that is expressed by virtually all cells in mice and non-human primates. They demonstrated antisense activity in many tissues and cell types, including liver, kidney, lung, muscle, adipose, adrenal gland, and peripheral nerves. The Generation 2.5 antisense compound was more effective in a wider range of tissues, according to the results presented in the article "Characterization of Target mRNA Reduction Through In Situ RNA Hybridization in Multiple Organ Systems Following Systemic Antisense Treatment in Animals."

"This seminal work addresses one of the most important questions facing the field, the demonstration and evaluation of multiple organ targeting by Nucleic Acid Therapeutics," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI. "This publication provides a benchmark for convergent analyses in multiple models for preclinical efficacy evaluation."

Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Graham C. Parker, PhD.

###

About the Journal Nucleic Acid Therapeutics is an authoritative, peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. Nucleic Acid Therapeutics is the official journal of the Oligonucleotide Therapeutics Society. Complete tables of content and a free sample issue may be viewed on the Nucleic Acid Therapeutics website.

About the Society

Here is the original post:
New study shows a breadth of antisense drug activity across many different organs

Are younger women more likely to have and die from a heart attack?

PUBLIC RELEASE DATE:

11-Dec-2013

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, December 10, 2013Young women, ages 55 years or below, are more likely to be hospitalized for an acute myocardial infarction (AMI) and to die within the first 30 days than men in the same age group, according to a new study published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Women's Health website at http://www.liebertpub.com/jwh.

In fact, although overall AMI hospitalization rates declined for both women and men from 2000-2009 in this Canadian study, the only increase was for younger women (<55 years), in whom the AMI rate rose 1.7% per year. Furthermore, Mona Izadnegahdar and coauthors, University of British Columbia and Providence Health Care Research Institute (Vancouver, BC), reported that the higher 30-day mortality rate for young women compared to young men persisted throughout the study period.

"These findings highlight the need for more aggressive strategies to reduce the incidence of AMI and improve outcomes after AMI in younger women," says Susan G. Kornstein, MD, Editor-in-Chief of Journal of Women's Health, Executive Director of the Virginia Commonwealth University Institute for Women's Health, Richmond, VA, and President of the Academy of Women's Health.

###

About the Journal

Journal of Women's Health, published monthly, is a core multidisciplinary journal dedicated to the diseases and conditions that hold greater risk for or are more prevalent among women, as well as diseases that present differently in women. The Journal covers the latest advances and clinical applications of new diagnostic procedures and therapeutic protocols for the prevention and management of women's healthcare issues. Complete tables of content and a sample issue may be viewed on the Journal of Women's Health website at http://www.liebertpub.com/jwh. Journal of Women's Health is the Official Journal of the Academy of Women's Health and the Society for Women's Health Research.

About the Academy

More here:
Are younger women more likely to have and die from a heart attack?

UK's Ministry of Nudges helps jobless

Alex Gyani had an idea, but even he considered it a little far-fetched.

A 24-year-old psychologist working for the British government, Mr. Gyani was supposed to come up with new ways to help people find work. He was intrigued by an obscure 1994 study that tracked a group of unemployed engineers in Texas. One group of engineers, who wrote about how it felt to lose their jobs, were twice as likely to find work as the ones who didn't. Mr. Gyani took the study to a job center in Essex, northeast of London, where he was assigned for several months. Sure, it seemed crazy, but would it hurt to give it a shot? Hayley Carney, one of the center's managers, was willing to try.

Ms. Carney walked up to a man slumped in a plastic chair in the waiting area as Mr. Gyani watched from across the room. The man 28, recently separated and unemployed for most of his adult life was "our most difficult case," Ms. Carney said later.

"How would you like to write about your feelings" about being out of a job? she asked the man. Write for 20 minutes. Once a week. Whatever pops into your head.

An awkward silence followed. Maybe this was a bad idea, Mr. Gyani remembers thinking.

But then the man shrugged. Why not? And so, every week, after seeing a job adviser, he would stay and write. He wrote about applying for dozens of jobs and rarely hearing back, about not having anything to get up for in the morning, about his wife who had left him. He would reread what he had written the week before, and then write again.

Over several weeks, his words became less jumbled. He started to gain confidence, and his job adviser noticed the change. Before the month was out, he got a full-time job in construction his first.

An Idea Born in America

Did the writing exercise help the man find a job? Even now it's hard for Mr. Gyani to say for sure. But it was the start of a successful research trial at the Essex job center one that is part of a much larger social experiment underway in Britain. A small band of psychologists and economists is quietly working to transform the nation's policy making. Inspired by behavioral science, the group fans out across the country to job centers, schools and local government offices and tweaks bureaucratic processes to better suit human nature. The goal is to see if small interventions that don't cost much can change behavior in large ways that serve both individuals and society.

It is an American idea, refined in American universities and popularized in 2008 with the best seller "Nudge," by Richard H. Thaler and Cass R. Sunstein. Professor Thaler, a contributor to the Economic View column in Sunday Business, is an economist at the University of Chicago, and Mr. Sunstein was a senior regulatory official in the Obama administration, where he applied behavioral findings to a range of regulatory policies, but didn't have the mandate or resources to run experiments.

See the article here:
UK's Ministry of Nudges helps jobless

APTUS Launches Universal Personal Assessment; Customer Demand and Market Momentum Drive Creation of New Product

Austin, TX (PRWEB) December 12, 2013

APTUS, a new interactive personal assessment company leveraging tablet technology and behavioral science, today announced the release of its new Universal personal assessment. APTUS Universal supports multiple markets including Corporate, Education, Medical, Military/Government and Sports.

We responded to customer demand by bringing our 30 minute innovative and interactive personal assessment to new markets. The APTUS Discovery is a paradigm-shift in personal assessments, providing a state of the art, unbiased, objective assessment using a dynamic platform, the tablet, said Mark Mangum, CEO of APTUS.

In development for 4 years and on the market since January 2013, The APTUS Discovery is a series of 10 game-like exercises administered on a tablet. The APTUS Discovery provides a set of real-time reports that show how a person Defines, Processes and Executes instructions and information across various contextual environments; essentially how one learns. APTUS leverages advancements in Behavioral Science and tablet technology to provide an individualized blueprint and path to development and growth never before thought possible.

For more information on APTUS, please visit http://www.APTUSDiscovery.com.

About APTUS Our mission is to change lives. We deliver ground breaking interactive, innovative and objective personal assessments that show how one Defines, Processes and Executes instructions and information across various contextual environments. APTUS measures 65 cognitive and behavioral attributes; we assess dynamically, while learning occurs. We are a competitive-edge.

See the original post:
APTUS Launches Universal Personal Assessment; Customer Demand and Market Momentum Drive Creation of New Product

More than 1,100 students expected to graduate at Clemson’s commencement ceremonies next week

More than 1,100 students are expected to receive degrees when Clemson University hosts its fall 2013 graduation ceremonies next Thursday, Dec. 19, at Littlejohn Coliseum.

Two ceremonies will be held that day: the first at 9:30 a.m. for the colleges of Business and Behavioral Science; and Health, Education and Human Development and the latter at 1:30 p.m. for the colleges of Agriculture, Forestry and Life Sciences; Architecture, Arts and Humanities; and Engineering and Science. Both ceremonies also will be streamed live online at http://www.clemson.edu.

The academic ceremonies are the final ones that President James Barker will preside over. He announced this past April that he planned to step down after 14 years. Jim Clements, who has been president of West Virginia University since 2009, will take over Jan. 1, 2014.

James Jim E. Rogers Jr., chairman of the board for Duke Energy, will receive an honorary doctor of humanities degree at graduation. Rogers foresight and business acumen led to the creation of Duke Energy, the nations largest electric utility, where he has also served as chairman, president and CEO.

Even before his tenure with Duke Energy, Rogers took a very progressive outlook in the energy sector, advocating investing in energy efficiency, modernizing the electric infrastructure and pursuing advanced technologies and nuclear energy to grow the economy and transition to a low-carbon future. He serves as vice chairman of the World Business Council for Sustainable Development and was honored by the Alliance to Save Energy with its Lifetime Achievement Award.

During his tenure as CEO, Duke Energy was recognized as a leader in sustainability. The company was twice named to the Dow Jones Sustainability World Index and part of the Dow Jones Sustainability Index for North America.

Rogers served as deputy general counsel for litigation and enforcement for the Federal Energy Regulatory Commission and as an expert commentator in media as diverse as 60 Minutes, The New York Times Magazine, CNBC and The Colbert Report. He has also testified more than 20 times before U.S. Congressional committees and international forums including the United Nations General Assembly, the World Economic Forum and the Clinton Global Initiative.

Rogers focus on innovation, creativity and sustainability is aligned with Clemsons commitment to environmental, economic and social stewardship. Duke Energy has been a partner with Clemson University both on campus and at the Clemson University Restoration Institute in North Charleston. At this interdisciplinary facility, Clemson University engineers and scientists will collaborate with other agencies and private industry to test next-generation energy systems. The overarching goal is to accelerate innovations to market and lower the cost of meeting the nations energy needs.

Born in 1947 in Birmingham, Ala., Rogers earned Bachelor of Business Administration and Juris Doctor degrees from the University of Kentucky. He and his wife, Mary Anne, have three children and 11 grandchildren.

Here is the original post:
More than 1,100 students expected to graduate at Clemson’s commencement ceremonies next week

7 beauty-boosting supplements

There are loads of anti-aging supplements out there that promise to make you look younger. We dove into research and talked to top dermatologists to find the few worth popping. Here, find seven with proven results.

1. Sun Protection Try: Fern Extract

Aside from daily use of a broad-spectrum SPF 30 sunscreen, boost your UV protection all year by taking an antioxidant supplement such as Heliocare ($60 for 60; pharmacies) or SunPill ($40 for 60; sunpill.com). New research from the University of Miami School of Medicine shows that the fern extract in these pills significantly reduced UVA-related DNA damage that leads to wrinkling and brown spots. For best results, pop one each day starting a week before you plan on fun in the sun. "This allows the antioxidants to build up in your system for maximum protection," says Dr. Leslie Baumann, a Miami Beach-based dermatologist.

If you're still skipping on sunscreen, you better think again. Here are the Sunscreen Excuses Even Smart Women Make.

2. Stop Breakage Try: Biotin

A daily 2.5 mg dose of the B vitamin biotin in good for swimmers or in the summer months when you're in the water more often. "This supplement helps prevent breakage from too much exposure to salt and chlorine," says Jin Soon Choi, owner of Jin Soon Natural Hand and Foot Spas. Research shows that a daily dose of the nutrient increases nail thickness by 25 percent, making nails less apt to split and tear.

3. Reverse Damage Try: Idebenone

It may be hard to pronounce, but idebenone (eh-DE-be-known) spells younger-looking skin. The antioxidant is small enough to penetrate deep into skin to repair damaged cells, says Dr. David McDaniel, an assistant professor of clinical dermatology at Eastern Virginia Medical School. Taken daily, Priori Idebenone Supplements ($60; prioriskincare.com for locations) defend your skin's health from the inside out.

For more tips to keep your skin looking young, learn the 10 Best Ways To Prevent Wrinkles.

4. Boost Skin, Hair & Nails Try: Primrose & Black Currant Oil

Go here to see the original:
7 beauty-boosting supplements

Stem Cells Therapy

Cell therapy Definition Cell therapy is the transplantation of human or animal cells to replace or repair damaged tissue. Purpose The purpose of cell therapy is to introduce cells into the body that will grow and replace damaged tissue. Cell therapy differs from conventional stem cell therapy in that the cells injected into the body in cell therapy are already differentiated (e.g., muscle cells, gland cells), whereas conventional stem cell therapy utilizes undifferentiated, usually embryonic cells. Cell therapy has long been used by alternative medicine practitioners who have claimed great benefits; these have not been replicated by conventional medical practitioners. Description The theory behind cell therapy has been in existence for several hundred years. The first recorded discussion of the concept of cell therapy can be traced to Phillippus Aureolus Paracelsus (1493-1541), a German-Swiss physician and alchemist who wrote in his Der grossen Wundartzney (Great Surgery Book) in 1536 that the heart heals the heart, lung heals the lung, spleen heals the spleen; like cures like. Paracelsus and many of his contemporaries agreed that the best way to treat an illness was to use living tissue to restore the ailing. In 1667, at a laboratory in the palace of Louis XIV, Jean-Baptiste Denis (1640-1704) attempted to transfuse blood from a calf into a mentally ill patient. Since blood transfusion is, in effect, a form of cell therapy, this could be the first documented case of this procedure. However, the first recorded attempt at non-blood cellular therapy occurred in 1912 when German physicians attempted to treat children with hypothyroidism (underactive thyroid gland), with thyroid cells. In 1931, Dr. Paul Niehans (1882-1971), a Swiss physician, became known as the father of cell therapy quite by chance. After a surgical accident by a colleague, Niehans attempted to replace a patients severely damaged parathyroid glands with those of a steer. When the patient began to rapidly deteriorate before the transplant could take place, Niehans decided to dice the steers parathyroid gland into fine pieces, mix the pieces in a saline solution, and inject them into the dying patient. He reported that immediately the patient began to improve and, in fact, lived for another 30 years. Cell therapy as alternative medicine Cell therapy as performed by alternative medicine practitioners is very different from the controlled research done by conventional stem cell medical researchers. Alternative practitioners refer to their form of cell therapy by several other different names including xenotransplant therapy, glandular therapy, and fresh cell therapy. The procedure involves the injection of either whole fetal xenogenic (animal) cells (e.g., from sheep, cows, pigs, and sharks) or cell extracts from human tissue. Several different types of cells may be administered simultaneously. Just as Paracelsuss theory of like cures like, the types of cells that are administered correspond in some way with the organ or tissue in the patient that is failing. In other words, the cells are not species specific, but only organ specific. Alternative practitioners cannot explain how this type of cell therapy works, but proponents claim that the injected cells travel to the similar organ from which they were taken to revitalize and stimulate that organs function and regenerate its cellular structure. Supporters of cellular treatment believe that embryonic and fetal animal tissue contain active therapeutic agents distinct from vitamins, minerals, hormones, or enzymes. This theory and these claims are rejected by practitioners of conventional medicine. Proponents of cell therapy claim that it has been used successfully to rebuild damaged cartilage in joints, repair spinal cord injuries, strengthen a weakened immune system, treat autoimmune diseases such as AIDS, and help patients with neurological disorders such as Alzheimers disease, Parkinsons disease, and epilepsy. Further claims of positive results have been made in the treatment of a wide range of chronic conditions such as arteriosclerosis, congenital defects, and sexual dysfunction. The therapy has also been used to treat cancer patients at a number of clinics in Tijuana, Mexico. Most of these claims are anecdotal. None of these application is supported by well-designed, controlled clinical studies. Key Terms Cell therapy as conventional medicine Cell therapy in conventional medicine is still in the research and early clinical trial stage. This research is an outgrowth of stem cell research, and is performed in government-regulated laboratories by traditionally trained scientists. Embryonic stem cells are cells taken from an embryo before they have differentiated (specialized) into such specific cell types as muscle cells, nerve cells, or skin cells. In laboratory test tube and animal experiments, stem cells often can be manipulated into differentiating into specific types cells that have the potential to replace differentiated cells in damaged organs. For example, in early 2008, researchers at the Diabetic Research Institute at the University of Miami in Florida were able to convert embryonic stem cells into insulin-producing cells and use them to treat insulin-dependent diabetes in mice. Stem cells also have been found in bone marrow, and work is underway to see if other cells can be manipulated into transforming into differentiated cells. In January 2009, researchers at Northwestern Universitys Feinberg School of Medicine in Chicago announced that they had used a patients own bone marrow stem cells to improve early symptoms of multiple sclerosis. Researchers noted improvement only in patients with early symptoms; in earlier research those with advanced symptoms had not improved. Other researchers are working on treating symptoms of muscular dystrophy with fully differentiated myoblasts (a kind of muscle cell) with mixed results. Still other are working with using cartilage cells (chondrocyte cells) to repair cartilage in joints such as the knee. Stem cell therapy has potential to treat a wide range of diseases and disorders, but it is, for the most part, still in the test tube and animal research stage of development. Because of the ethical questions raised when the harvesting of stem cells destroys embryos, the United States has placed restrictions on some human stem cell research. These restrictions, however, do not apply to research that does not destroy embryos. However, much stem cell research is being carried out in other countries, especially Thailand, South Korea, and China, where fewer restrictions are placed on obtaining human stem cells for experimentation. A list of FDA-approved clinical trials involving stem cell therapy can be found at http://www.clinicaltrials.gov. Preparations Alternative practitioners use several processes to prepare cells for use. One procedure involves extracting cells from the patient and then culturing them in a laboratory until they multiply to the level needed for transplantation back into the same patient. Another procedure uses freshly removed fetal animal tissue that has been processed and suspended in a saline (salt water) solution. The preparation of fresh cells then may be either injected immediately into the patient or preserved by being freeze-dried or deep-frozen in liquid nitrogen before being injected. Injected cells may or may not be tested for pathogens, such as bacteria, viruses, or parasites, before use. Conventional cell therapy researchers work in laboratories where the growing environment of the cells is highly controlled and monitored to prevent contamination. Precautions Many forms of cell therapy in the United States are highly experimental procedures. Patients should approach any cell therapy treatments with extreme caution, inquire about their proven efficacy and legal use in the United States or their home country, and should only accept treatment only from a licensed physician who should educate the patient completely on the risks and possible side effects involved with cell therapy. These same cautions apply for patients interested in participating in FDA-approved clinical trials of cell therapy treatments. Side effects Because cell therapy encompasses a wide range of treatments and applications and many of these treatments are unproven and highly experimental, the full range of possible side effects of the treatments is not yet known. Anaphylactic shock, immune system reactions, and encephalitis are just a few of the known reported side effects in some patients to date. Patients undergoing cell therapy treatments which use cells transplanted from animals or other humans run the risk of cell rejection, in which the body recognizes the cells as a foreign substance and uses immune system cells to attack and destroy them. Some forms of cell therapy use special coatings on the cells in an attempt to trick the immune system into recognizing the new cells as native to the body. There is also the chance of the cell solution transmitting a bacterial, viral, fungal, or parasitic infection to the patient. Careful screening and testing of cells for pathogens can reduce this risk. Research and general acceptance Cell therapy as alternative healers practice it is generally rejected as effective by the traditionally-trained scientific community. Most of the claims made for these therapies are based on anecdotal evidence and are not backed by controlled clinical trials. While some mainstream cell therapy procedures have shown some success in clinical studies, others are still largely unproven, including cell therapy for cancer treatment. Until large, controlled human clinical studies are performed on cell therapy procedures, they will remain fringe treatments. For Your Information Resources Books Steenblock, David and Anthony G. Payne.Umbilical Cord Stem Cell Therapy: The Gift of Healing from Healthy Newborns. Laguna Beach, CA: Basic Health Publications, 2006. Periodicals Pollack, Andrew. Stem Cell Therapy Controls Diabetes in Mice. New York Times. February 21, 2007 [cited February 2, 2009] http://www.nytimes.com/2008/02/21/health/research/21stem.html. Websites Cellular Therapy. Quackwatch. 2003 [cited February 2, 2009]. http://www.quackwatch.com/01QuackeryRelatedTopics/Cancer/cellular.html. Multiple Sclerosis Reversed with Stem Cell Therapy. New Scientist Health. January 30, 2009 [cited February 2, 2009]. http://www.newscientist.com/article/dn16509-multiple-sclerosis-reversed-with-stem-cell-therapy.html. Organizations Alternative Medicine Foundation. P. O. Box 60016, Potomac, MD 20859. (301) 340-1960. http://www.amfoundation.org. Center for Cell and Gene Therapy. Baylor College of Medicine. One Baylor Place N1002, Houston, TX 77030 (713) 798-1246. http://www.bcm.edu/genetherapy. Cell therapy

Cell Therapy

Alternative-Fringe medicine (1) Live cell therapy (2) The injection of cellular material from organs, foetuses, or embryos of animals to stimulate healing, counteract the effects of ageing, and treat a variety of degenerative diseases such as arthritis, Parkinsons disease, atherosclerosis, and cancer; methods include the use of live cells, freeze-dried cells, cells from specific organs, and whole embryo preparations Molecular medicine (1) Gene therapy, see there (2) Stem cell therapy Quackery Sicca cell treatment

cell

1. the basic structural unit of living organisms.

2. a small more or less enclosed space.

All living cells arise from other cells, either by division of one cell to make two, as in mitosis and meiosis, or by fusion of two cells to make one, as in the union of the sperm and ovum to make the zygote in sexual reproduction.

All cells are bounded by a structure called the cell membrane or plasma membrane, which is a lipid bilayer composed of two layers of phospholipids. Each layer is one molecule thick with the charged, hydrophilic end of the lipid molecules on the surface of the membrane and the uncharged hydrophobic fatty acid tails in the interior of the membrane.

Cells are divided into two classes, eukaryotic cells and prokaryotic cells:

Prokaryotic cells, the bacteria, have no nucleus, and their genetic material, consisting of a single circular naked DNA molecule, is not separated from the rest of the cell by a nuclear membrane.

Original post:
Stem Cells Therapy

A4M Special Information Center

Anti-aging medicine is founded on the application of advanced scientific and medical technologies for the early detection, prevention, treatment, and reversal of age-related dysfunction, disorders, and diseases. It is a healthcare model promoting innovative science and research to prolong the healthy lifespan in humans. As such, anti-aging medicine is based on principles of sound and responsible medical care that are consistent with those applied in other preventive health specialties. The phrase "anti-aging," as such, relates to the application of advanced biomedical technologies focused on the early detection, prevention, and treatment of aging-related disease. The goal of anti-aging medicine is not to merely prolong the total years of an individual's life, but to ensure that those years are enjoyed in a productive and vital fashion. Founded in 1992, The American Academy of Anti-Aging Medicine (A4M) is a US federally registered non-profit professional organization of 26,000 member physicians, health professionals, and scientists from 120 nations who are dedicated to the advancement of technology to detect, prevent, and treat aging related disease and to promote research into methods to retard and optimize the human aging process. Serving as a leading advocate for the new clinical specialty of anti-aging medical science, the A4M is the world's largest professional organization dedicated to advancing research and clinical pursuits that enhance the quality, and extend the quantity, of the human lifespan. Welcome to the A4M Special Information Center. We invite you to learn more about the A4M and our media and publishing endeavors that support the A4M's educational mission.

The American Academy of Anti-Aging Medicine, Inc. ("A4M") is a non-profit medical society dedicated to the advancement of technology to detect, prevent, and treat aging related disease and to promote research into methods to retard and optimize the human aging process. A4M is also dedicated to educating physicians, scientists, and members of the public on biomedical sciences, breaking technologies, and anti-aging issues. A4M believes that the disabilities associated with normal aging are caused by physiological dysfunction which in many cases are ameliorable to medical treatment, such that the human lifespan can be increased, and the quality of one's life enhanced as one grows chronologically older. A4M seeks to disseminate information concerning innovative science and research as well as treatment modalities designed to prolong the human lifespan. Anti-Aging Medicine is based on the scientific principles of responsible medical care consistent with those of other healthcare specialties. Although A4M seeks to disseminate information on many types of medical treatments, it does not promote or endorse any specific treatment nor does it sell or endorse any commercial product.

Read this article:
A4M Special Information Center

BioVision 2010: “Principles of Neural Ensemble Physiology” – Video


BioVision 2010: "Principles of Neural Ensemble Physiology"
The Theory of Biorobs: Towards the Future part II was held during BioVision Alexandria 2010 conference "New Life Sciences: Future Prospects" on Tuesday, 13 April 2010 at the Bibliotheca Alexandrina...

By: Bibliotheca Alexandrina Channel

Read the original post:
BioVision 2010: "Principles of Neural Ensemble Physiology" - Video